Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia - PubMed (original) (raw)

Review

Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia

Vicki Oldfield et al. Drugs. 2006.

Abstract

Intravenous rasburicase (Elitek, Fasturtec) is the first recombinant uricolytic agent. It is indicated for the management of anticancer therapy-induced hyperuricaemia in paediatric patients in the EU and US, and in adult patients in the EU. Rasburicase is effective and generally well tolerated in adult and paediatric patients with, or at risk of developing, anticancer therapy-induced hyperuricaemia. It is associated with potentially serious haematological adverse events and hypersensitivity reactions, which must be considered prior to and during administration; rasburicase is contraindicated in patients predisposed to haemolysis or methaemoglobinaemia and in patients with glucose-6-phosphate dehydrogenase deficiency. Unlike allopurinol, rasburicase acts on existing uric acid concentrations. Rasburicase treatment resulted in significantly less systemic exposure to uric acid and a quicker therapeutic response than allopurinol in paediatric patients; further studies are needed to determine the comparative efficacy and tolerability of rasburicase versus allopurinol in adult patients. Although further pharmacoeconomic data would be useful, rasburicase was most cost effective for the prevention of hyperuricaemia in children and for treatment of this condition in adults. Thus, rasburicase is a useful option for the prophylaxis or treatment of anticancer therapy-induced hyperuricaemia in both adult and paediatric patients.

PubMed Disclaimer

Similar articles

• Spotlight on rasburicase in anticancer therapy-induced hyperuricemia.
  Oldfield V, Perry CM. Oldfield V, et al. BioDrugs. 2006;20(3):197-9. doi: 10.2165/00063030-200620030-00008. BioDrugs. 2006. PMID: 16724869 Review.
• Rasburicase: a potent uricolytic agent.
  Pui CH. Pui CH. Expert Opin Pharmacother. 2002 Apr;3(4):433-42. doi: 10.1517/14656566.3.4.433. Expert Opin Pharmacother. 2002. PMID: 11934348 Review.
• Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
  Feng X, Dong K, Pham D, Pence S, Inciardi J, Bhutada NS. Feng X, et al. J Clin Pharm Ther. 2013 Aug;38(4):301-8. doi: 10.1111/jcpt.12061. Epub 2013 Apr 3. J Clin Pharm Ther. 2013. PMID: 23550846
• Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.
  Campara M, Shord SS, Haaf CM. Campara M, et al. J Clin Pharm Ther. 2009 Apr;34(2):207-13. doi: 10.1111/j.1365-2710.2008.00994.x. J Clin Pharm Ther. 2009. PMID: 19250141
• Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
  Kennedy LD, Ajiboye VO. Kennedy LD, et al. J Oncol Pharm Pract. 2010 Sep;16(3):205-13. doi: 10.1177/1078155209348719. Epub 2009 Nov 18. J Oncol Pharm Pract. 2010. PMID: 19923162 Review.

Cited by

• A retrospective analysis of preemptive pharmacogenomic testing in 22,918 individuals from China.
  Huang Q, Liao Y, Yu T, Lei W, Liang H, Wen J, Liu Q, Chen Y, Huang K, Jing L, Huang X, Liu Y, Yu X, Su K, Liu T, Yang L, Huang M. Huang Q, et al. J Clin Lab Anal. 2023 Mar;37(5):e24855. doi: 10.1002/jcla.24855. Epub 2023 Mar 14. J Clin Lab Anal. 2023. PMID: 36916827 Free PMC article.
• Microreactor equipped with naturally acid-resistant histidine ammonia lyase from an extremophile.
  Ade C, Marcelino TF, Dulchavsky M, Wu K, Bardwell JCA, Städler B. Ade C, et al. Mater Adv. 2022 Apr 21;3(8):3649-3662. doi: 10.1039/d2ma00051b. Epub 2022 Mar 29. Mater Adv. 2022. PMID: 36238657 Free PMC article.
• Rasburicase-induced haemolysis and methemoglobinemia: an ongoing issue.
  Madanat L, Schoenherr D, Wey E, Gupta R. Madanat L, et al. BMJ Case Rep. 2021 Mar 16;14(3):e240967. doi: 10.1136/bcr-2020-240967. BMJ Case Rep. 2021. PMID: 33727299 Free PMC article.
• Uric acid in plants and microorganisms: Biological applications and genetics - A review.
  Hafez RM, Abdel-Rahman TM, Naguib RM. Hafez RM, et al. J Adv Res. 2017 Sep;8(5):475-486. doi: 10.1016/j.jare.2017.05.003. Epub 2017 May 11. J Adv Res. 2017. PMID: 28748114 Free PMC article. Review.
• Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase.
  Usami E, Kimura M, Iwai M, Teramachi H, Yoshimura T. Usami E, et al. Mol Clin Oncol. 2017 Jun;6(6):955-959. doi: 10.3892/mco.2017.1232. Epub 2017 Apr 28. Mol Clin Oncol. 2017. PMID: 28588796 Free PMC article.

References

1. 1. Pediatr Blood Cancer. 2006 Apr;46(4):439-45 - PubMed
2. 1. J Clin Oncol. 2001 Feb 1;19(3):697-704 - PubMed
3. 1. Acta Haematol. 2006;115(1-2):35-8 - PubMed
4. 1. Am J Med. 2004 Apr 15;116(8):546-54 - PubMed
5. 1. Contrib Nephrol. 2005;147:69-79 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Other Literature Sources

  • The Lens - Patent Citations